Long-term prognosis of clinically early IgA nephropathy is not always favorable by Hajeong Lee et al.
Lee et al. BMC Nephrology 2014, 15:94
http://www.biomedcentral.com/1471-2369/15/94RESEARCH ARTICLE Open AccessLong-term prognosis of clinically early IgA
nephropathy is not always favorable
Hajeong Lee1, Jin Ho Hwang2, Jin Ho Paik3, Hyun Jin Ryu1, Dong Ki Kim1, Ho Jun Chin4, Yun Kyu Oh5,
Kwon Wook Joo1, Chun Soo Lim5, Yon Su Kim1 and Jung Pyo Lee5*Abstract
Background: The long-term prognosis of clinically early IgA nephropathy (IgAN) patients remains to be clarified.
We investigated the long-term outcomes of IgAN patients with an apparently benign presentation and evaluated
prognostic factors for renal survival.
Methods: We included patients with biopsy-proven IgAN who had estimated glomerular filtration rates
(eGFR) ≥60 mL/min/1.73 m2, normal blood pressure, and proteinuria <0.5 g/day at the time of biopsy. The primary
outcome was progression to end-stage renal disease (ESRD). The secondary outcome was a 50% increase in serum
creatinine level or an increase in proteinuria to >1 g/day.
Results: The analysis included 153 patients who met the inclusion criteria. At diagnosis, their median systolic
blood pressure was 120 (110–130) mmHg, eGFR was 85.9 (74.9–100.1) mL/min/1.73 m2, and proteinuria was
0.25 (0.13–0.38) g/day. Of these, 4 patients died and 6 reached ESRD. The 30-year renal survival rate was 85.5%.
Three patients had increased serum creatinine levels and 11 developed proteinuria. Remission was observed in
35 (22.9%) patients. A moderate or severe degree of interstitial fibrosis (adjusted odd ratio [OR] 5.93, 95%
confidence interval [CI] 1.44–24.45, P = 0.014) and hypoalbuminemia (adjusted OR 6.18, 95% CI 1.20–31.79, P = 0.029)
were independent predictors of the secondary outcome.
Conclusions: This study showed that the prognosis of early IgAN was not always favorable, even resulting in
progression to ESRD in some cases. Hypoalbuminemia and interstitial fibrosis should also be considered
important prognostic factors in clinically early IgAN patients.
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IgA nephropathy (IgAN) is a common glomerular dis-
ease and an important cause of kidney failure. This dis-
ease accounts for more than half of all forms of primary
glomerulonephritis in Korea [1]. Although dominant
mesangial IgA deposits represent the diagnostic hall-
mark of IgAN, its clinical features are highly variable,
ranging from simple hematuria with or without pro-
teinuria to a rapidly progressive loss of renal function.
Therefore, the renal survival and risk factors of long-
term IgAN patients have been studied extensively over
the last 30 years [2]. Previous studies indicate that the* Correspondence: nephrolee@gmail.com
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unless otherwise stated.likelihood of dialysis or death can be estimated using
three clinical risk factors: urinary protein excretion of
more than 1 g/day, high blood pressure exceeding
140/90 mmHg, and a decreased estimated glomerular fil-
tration rate (eGFR) of less than 60 mL/min/1.73 m2 [3].
Among patients with all three risk factors, about 70–80%
reached end-stage renal disease (ESRD) and 45% died
within 30 years [4,5]. These clinical prognostic factors
also independently predict a poor clinical course. How-
ever, information on the long-term outcomes of IgAN
patients with a minor presentation is scarce.
Only a few studies have focused on long-term patient
and renal outcomes in IgAN patients who had a renal
biopsy performed for microscopic hematuria, normal
renal function, and minimal proteinuria. Moreover, the
results of previous studies are controversial. A recently. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain




• Inadequate biopsy (n=9)
• eGFR <60 mL/min per 1.73m2 (n=594)
• Proteinuria ≥ 0.5 g/day (n=1322)
• Secondary cause (n=52)
• Follow up duration less than 12 months (n = 248)
Analysis 
(n=153)
Figure 1 Participation flow diagram.
Lee et al. BMC Nephrology 2014, 15:94 Page 2 of 9
http://www.biomedcentral.com/1471-2369/15/94published European cohort study found that IgAN pa-
tients who presented with minor urinary abnormalities
and normal renal function did not progress to ESRD,
and that more than one-third of patients achieved clin-
ical remission [6]. Research performed in Hong Kong,
however, found that 33% of patients with minimal pro-
teinuria and preserved renal function developed more
than 1 g/day of proteinuria [7,8]. In a cohort of Chinese
IgAN patients with isolated microscopic hematuria who
were followed for up to 12 years, a decrease in renal
function was observed in 24% [9]. These studies suggest
that IgAN patients require long-term follow-up due to
the potential for progressive disease.
Our previously, reported findings on the mortality
of IgAN patients, which were obtained from our long-
term follow-up data [4], did not significantly differ from
European data [10]. The present study focused on long-
term outcomes and prognostic factors for renal survival
in clinically early IgAN patients. We hypothesized that
even patients presenting with benign manifestations
would progress during long-term follow-up.
Methods
Ethics statement
Ethical approval was obtained from the Institutional
Review Board of Seoul National University Hospital
(H–1010–055–336), and this study was conducted in
accordance with the principles of the Declaration of
Helsinki. As the study was retrospective in design and did
not involve any interventions, the Institutional Review
Board waived informed consent for this study.
Study subjects
From 1979 to 2012, a total of 1,613 adult patients were
diagnosed with IgAN based on immunofluorescence
microscopy showing mesangial IgA deposition as the
predominant or co-dominant immunoglobulin. We
included IgAN patients with preserved renal function
(eGFR ≥60 mL/min/1.73 m2) and minimal proteinuria
(urinary protein-to-creatinine ratio <0.5 g/g creatinine or
24-h urinary protein <0.5 g/day). We excluded patients
with fewer than 5 glomeruli per biopsy section and those
in whom IgAN was the result of secondary causes, as
indicated by clinical or laboratory evidence of systemic
lupus erythematosus, Henoch-Schonlein nephritis, or
liver cirrhosis. Patients who were followed for less than
12 months were also excluded. Ultimately, a total of 153
remaining patients were analyzed (Figure 1).
Clinical parameters
Clinical information was collected from a review of com-
puterized medical records. Demographic factors, includ-
ing age, sex, body mass index, and blood pressure at
the time of renal biopsy, were obtained. Blood and urinechemistry parameters were extensively reviewed from the
time of renal biopsy to the time of last follow-up. Until
2010, serum creatinine levels were measured by Jaffe kin-
etic alkaline picrate method using a Hitachi 7600 analyzer
(Toshiba, 200FR, Tokyo, Japan). Serum creatinine levels
were re-calibrated to an isotope-dilution mass spectrom-
etry assay (Roche diagnostic). The correction equation is as
follows: recalibrated serum creatinine = 1.0734 x measured
serum creatinine(−0.2418). The eGFR was calculated using
the Modification of Diet in Renal Disease equation [11,12].
Proteinuria was assessed using either a random urine pro-
tein to creatinine ratio (normal range, <0.2 g/g creatinine)
or 24-h urinary protein measurement. Information on
treatments prescribed during the follow-up period was
collected, including exposure to immunosuppressive
agents and to renin-angiotensin system (RAS) blockade by
angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers.
Pathological parameters
All native renal biopsies were processed according to
light microscopy, immunofluorescence, and electron mi-
croscopy standard techniques. Histopathological changes
were evaluated by, two pathologists who reviewed the
renal biopsy slides. All IgAN biopsies were staged ac-
cording to the WHO grading system [13]. The proportions
of global sclerosis, segmental sclerosis, and crescent forma-
tion in the glomerular area were calculated using results
obtained on light microscopy. Mesangial proliferation was
also graded as none or minimal, mild, moderate, and se-
vere. In the tubulointerstitial area, the degrees of tubular
atrophy (TA), interstitial fibrosis (IF), and interstitial in-
flammation were graded semi-quantitatively as follows:
none or minimal, mild, moderate, and severe.
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The primary outcome was ESRD progression or patient
death. The start of the follow-up period was taken as the
date of renal biopsy. ESRD was defined as progression to
eGFR <15 mL/min/1.73 m2, initiation of permanent dia-
lysis, or kidney transplantation. Data on mortality were
obtained from the Korean National Statistical Office,
and those on ESRD were collected from the Korean
ESRD registry [14,15]. We combined all these data ac-
cording to the unique identification number issued to all
Koreans. The secondary outcome was renal progression,
defined as a 50% serum creatinine increase or the devel-
opment of proteinuria greater than 1 g/day. We also
evaluated patient clinical remission, defined as the
disappearance of microscopic hematuria confirmed on
more than 3 occasions, proteinuria persistently lower
than 0.2 g/day, and normal renal function.
Statistical analysis
The data are presented as frequencies and percentages
for categorical variables. Continuous variables are shown
as medians and interquartile ranges (IQR). Comparisons
between the outcome group and other groups were per-
formed using the χ2 test for dichotomous variables and
the Mann–Whitney test for asymmetric continuous vari-
ables. Cumulative renal survival was determined by the
Kaplan-Meier method. Non-renal deaths were excluded
from the renal survival rate analysis. The renal survival
time for each patient was computed from the time of
renal biopsy to the last follow-up. Associations between
baseline variables and outcomes were tested using logis-
tic regression. Potential confounding variables identi-
fied a priori included hypoalbuminemia (serum albumin
level, <3.5 g/dL), RAS blockade, and pathological changes
such as segmental sclerosis, interstitial fibrosis, and tubular
atrophy. Variables that showed a significant association
(p <0.10) in the univariate analysis or were of consid-
erable theoretical relevance were entered into the multi-
variate stepwise logistic regression models. Analyses were
performed using the SPSS software package (version
20.0, Chicago, IL, USA). All tests were two-tailed, with
P-values <0.05 considered statistically significant.
Results
Baseline characteristics
Considering the exclusion criteria described above, a
total of 153 (9.5%) patients were included in the final
analyses. The median follow-up duration was 95 (38–
207) months. Patient demographic information is sum-
marized in Table 1. The age at the time of biopsy was 26
(20–36) years, and 43.8% of patients were male. The ini-
tial eGFR was 85.9 (74.9–100.1) mL/min/1.73 m2 and
systolic blood pressure was 120 (110–130) mmHg. The
median value of proteinuria was 0.25 (0.13–0.38) g/day.Approximately 43% of the patients were prescribed
RAS blockers during the follow-up period. No patient
was treated with immunosuppressive agents including
corticosteroids.
In the histopathological review, more than half of the
patients showed minimal or mild pathological change
while 47 (30.7%) patients had advanced pathological
change, with WHO grade higher than III. Glomerular
crescent formation was found in 9.2% of the patients.
Moreover, more than 12% of patients had a moderate to
severe degree of mesangial proliferation, TA or IF.
Primary outcomes
During the observation period, 6 patients developed
ESRD and 4 patients died. The 30-year renal survival
rate was 85.5% (Figure 2). The details of patients who
reached to ESRD are described in Table 2. Although they
had preserved renal function and minimal proteinuria at
the time of biopsy, half of the patients had an advanced
pathological grade relative to their clinical manifestation.
Two patients had segmental sclerosis, and one had mod-
erate degree of TA/interstitial inflammation. None of the
patients who reached ESRD showed crescent formation
or vascular structural change. Time to ESRD ranged
from 5 to 19 years. Four patients died. One patient died
subsequent to ESRD progression. However, the remaining
3 patients died with functioning kidneys. The patient in
whom renal failure progressed to ESRD 153 months fol-
lowing kidney biopsy, died 142 months after peritoneal
dialysis was initiated. The cause of death was colonic
pseudo-obstruction and intestinal perforation. Causes of
death in the patients who had died with functioning kid-
neys were traffic accident in one case, ovarian cancer in
one case, and unknown in the other cases.
Secondary outcomes
Secondary outcomes could be analyzed in 118 of the 153
patients, for whom renal function and urinalysis data
were available. Three patients showed a greater than
50% increase of serum creatinine levels compared with
those at baseline. Eleven patients developed proteinuria
with protein levels of at least 1.0 g/day during the
follow-up period. The baseline clinical characteristics of
progressive patients were similar to those of stable patients
(Table 3). However, patients who met the secondary out-
come had a higher frequency of segmental sclerosis (35.7%
vs 8.7%, P = 0.012), IF of more than a moderate degree
(35.7% vs 7.8%, P = 0.009), and RAS blockade use (84.6% vs
45.4%, P = 0.009).
Predictors of outcome
Table 4 shows the results of predictor analyses ac-
cording to secondary and composite outcomes. For the
primary outcome, we failed to identify any clinical or
Table 1 Baseline clinical characteristics of early IgAN patients
Variables Values
Age (years) 26 (20–36)
Sex (male,%) 60 (43.8%)
Body mass index (kg/m2) 21.2 (20.0–23.5)
Systolic blood pressure (mmHg) 120 (110–130)
Serum creatinine (mg/dL) 0.90 (0.80–1.09)
eGFR (mL/min/1.73 m2) 85.9 (74.9–100.1)
Proteinuria (g/day) 0.25 (0.11–0.38)
Serum cholesterol (mg/dL) 159 (144–185)
Serum albumin (g/dL) 4.1 (3.9–4.4)
Plasma hemoglobin (g/dL) 13.2 (12.3–14.4)
Serum IgA (mg/dL) 302 (223–417)
Follow up duration (months) 95 (38–207)
RAS blockade (N,%) 66 (43%)
Glomerulus number 37 (20–58)
Global sclerosis (%) 4.0 (0–11.0)
Segmental sclerosis (%) 0 (0–5.0)
Crescent formation (yes,%) 14 (9.2%)
WHO grade I II III IV
19 (12.4%) 84 (54.9%) 37 (24.2%) 10 (6.5%)
None Mild Moderate Severe
Mesangial proliferation (yes,%) 16 (10.7%) 114 (74.5%) 16 (10.7%) 4 (2.6%)
Tubular atrophy (yes,%) 43 (28.1%) 85 (55.6%) 19 (12.4%) 2 (1.3%)
Interstitial fibrosis (yes,%) 30 (19.6%) 100 (65.4%) 17 (11.1%) 2 (1.3%)
Interstitial inflammation (yes,%) 38 (24.8%) 110 (71.9%) 1 (0.7%) 0 (0.0%)
Continuous variables are presented by median (interquartile range). Categorical variables are presented by frequency (percentage). eGFR, estimated glomerular
filtration rate; RAS, renin–angiotensin system.
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poalbuminemia < 3.5 g/dL, global and segmental scler-
osis, IF, TA, and RAS blockader use were identified as
potential predictors of the secondary outcomes. After
the multivariate analysis, only hypoalbuminemia (odds
ratio [OR] 11.89, 95% CI 2.10–67.23, P = 0.005) and IF
(OR 5.93, 95% CI 1.44–24.45, P = 0.014) remained as inde-
pendent risk factors. Regression analyses of a composite of
the primary and secondary outcomes showed similar re-
sults to analyses of the secondary outcome. Both hypoal-
buminemia (OR 6.18, 95% CI 1.20–31.79, P = 0.029) and
IF (OR 3.82, 95% CI 1.11–13.11, P = 0.033) remained inde-
pendent determinants of the composite outcome.
Clinical remission
During follow-up, 36 (31.0%) patients showed loss of
proteinuria or microscopic hematuria along with stable
blood pressure and renal function, in other words, clin-
ical remission. Patients who achieved clinical remis-
sion had low systolic blood pressures (median [IQR], 114[110–124] mmHg vs 120 [110–120] mmHg), less TA
(11.4% vs 12.5%) and less IF (8.6% vs 11.3%). However,
these differences were all statistically non-significant.
Only the amount of proteinuria (0.28 [0.13–0.41] vs
0.21 [0.09–0.33], P = 0.021) and prescription of RAS
blockade (34.3% vs 56.3%, P = 0.042) differed signifi-
cantly according to clinical remission. Our regression
analysis did not find any predictors of clinical remission
(data not shown).
Discussion
The clinical course of IgAN is highly variable. However,
it is essential to determine whether a patient is at high
risk for renal insufficiency in order to establish an indi-
vidualized management plan. Forecasting the prognosis
of benign IgAN on the basis of the currently known
prognostic factors or modeling systems is challenging.
Experience gathered over a sufficient observation period
is essential to address these patients’ renal survival.
Based on our long follow-up period, we demonstrated that
No at risk 152 101 58 45 32 24 4
93.7%
85.5% 85.5%
Figure 2 Cumulative renal and patient survival after kidney biopsy in early IgAN patients. The primary endpoint is free of death or end
stage renal disease. The number of patients remaining at 60, 120, 180, 240, 300 and 360 months of follow–up are shown at the bottom.
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disease trajectory in Korea. More than moderate degree of
IF and hypoalbuminemia were independent predictors of
renal progression. This study is uniquely placed to clarify
the prognosis of clinically early IgAN.Table 2 Clinical manifestation of patients who reached to end
Patient A Patient B
Body mass index (kg/m2) 24.6 Unknown
Blood pressure (mmHg) 110/10 130/90
Blood urea nitrogen (mg/dL) [10-26] 9 17
Serum creatinine (mg/dL) [0.70–1.40] 1.00 1.20
Creatinine clearance (mL/min) 78.5 NA
eGFR (mL/min/1.73 m2) 72.1 74.1
Serum albumin (g/dL) [3.3–5.2] 4.6 4.9
Proteinuria (g/day) 0.21 0.22
WHO grade III II
Global sclerosis (N/Glom No) 0/19 1/15
Segmental sclerosis (N/Glom No) 0/19 0/15
Crescent formation (N/Glom No) 0/19 0/15
Mesangial proliferation None Mild
Tubular atrophy Mild None
Interstitial fibrosis None None
Interstitial inflammation Mild None
Vascular change None None
Time to ESRD (months) 153 224
Continuous variables are presented by median (interquartile range). Categorical var
filtration rate; RAS, renin–angiotensin system.Our results are similar to those of previous Chinese
and Japanese studies [8,9,16,17], and are contrary to
those of a recent European study [6] (Table 5). In particu-
lar, our results evoke awareness of the fact that, even with
a clearly benign initial presentation, IgAN patients can–stage renal disease
Patient C Patient D Patient E Patient F
18.3 21.6 23.2 21.4
100/70 110/70 110/70 100/60
12 12 12 NA
0.90 1.20 0.70 1.30
84 87 NA 66
77.1 82.7 152.4 74.6
3.5 4.4 4.0 NA
0.35 0.34 0.18 0.20
II III III NA
0/8 2/32 1/35 0/5
0/8 2/32 2/35 0/5
0/8 0/32 0/35 0/5
None Mild Mild Moderate
None Moderate Mild NA
None Mild Mild NA
Mild Moderate None NA
None None None None
101 100 58 159
iables are presented by frequency (percentage). eGFR, estimated glomerular
Table 3 Comparison between patients with secondary renal outcome and those without
Variables Renal outcome (−) Renal outcome (+) P–value
N 104 14
Age at the time of biopsy (years) 26 (19–37) 27 (25–35) 0.640
Sex (male, %) 47/104 (45.2%) 3/14 (21.4%) 0.148
Body mass index (kg/m2) 21.6 (19.9–23.5) 21.7 (20.5–23.1) 0.749
Systolic blood pressure (mmHg) 120 (110–126) 115 (110–130) 0.990
Serum creatinine (mg/dL) 0.90 (0.80–1.04) 0.80 (0.70–0.90) 0.016
eGFR (ml/min/1.73 m2) 86.4 (74.9–105.6) 93.0 (82.5–113.2) 0.142
Albumin (g/dL) 4.1 (3.9–4.4) 3.9 (3.5–4.3) 0.038
Proteinuria (g/day) 0.25 (0.10–0.40) 0.28 (0.10–0.41) 0.680
WHO grade 2.0 (2.0–2.0) 2.5 (2.0–3.0) 0.047
Global sclerosis≥ 10% 32/104 (30.8%) 8/14 (57.1%) 0.214
Segmental sclerosis ≥ 10% 9/104 (8.7%) 5/14 (35.7%) 0.012
Cresent 10/104 (9.6%) 1/14 (7.1%) 1.000
Mesangial proliferation 15/103 (14.6%) 3/14 (21.4%) 0.450
Interstitial fibrosis 8/103 (7.8%) 5/14 (35.7%) 0.009
Interstitial inflammation 1/103 (1.0%) 0/14 (0.0%) 1.000
Tubular atrophy 11/103 (10.7%) 5/14 (35.7%) 0.024
RAS blockade (N, %) 48/103 (45.4%) 12/14 (84.6%) 0.009
Table 4 Univariate and multivariate logistic regression
analysis for development of outcome
Variables Wald OR (95% CI) P–value
Secondary outcome
Univariate
Hypoalbuminemia 9.68 13.33 (2.61–68.19) 0.002
Global sclerosis 3.58 3.00 (0.96–9.36) 0.058
Segmental sclerosis 7.23 5.86 (1.62–21.29) 0.007
Interstitial fibrosis 7.97 6.60 (1.78–24.45) 0.005
Tubular atrophy 5.72 4.65 (1.32–16.37) 0.017
Use of RAS blockade 5.97 6.88 (1.47–32.27) 0.015
Multivariate analysis
Hypoalbuminemia 7.85 11.89 (2.10–67.23) 0.005
Interstitial fibrosis 6.06 5.93 (1.44–24.45) 0.014
Composite outcome
Univariate
Hypoalbuminemia 5.99 7.19 (1.48–34.86) 0.014
Segmental sclerosis 2.89 2.84 (0.85–9.47) 0.089
Interstitial fibrosis 5.85 4.31 (1.32–14.09) 0.016
Tubular atrophy 3.72 3.03 (0.98–9.47) 0.054
Multivariate analysis
Hypoalbuminemia 4.75 6.18 (1.20–31.79) 0.029
Interstitial fibrosis 4.53 3.82 (1.11–13.11) 0.033
Continuous variables are presented by median (interquartile range).
Categorical variables are presented by frequency (percentage). eGFR,
estimated glomerular filtration rate; RAS, renin–angiotensin system.
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hort, one in every 25 early IgAN patients progressed to
ESRD during their lifetimes. Such an observation has not
been reported previously. Considering that baseline char-
acteristics among previous studies were similar, the cause
of the varying prognosis of clinically early IgAN requires
investigation. One possible explanation is the difference
in the definition of outcomes. In the Chinese studies,
renal progression was defined only in terms of worsening
and not in relation to initial renal function [8,9]. Con-
versely, the European study defined renal progression as
an increase in serum creatinine levels of ≥50% from ini-
tial levels or ESRD progression. However, our study sepa-
rated ESRD progression and impaired renal function, and
our definition of impaired renal function was derived
from the European study. Our data indicate that the
prognosis of early IgAN patients is relatively worse than
that of similar European IgAN patients even when a
comparable outcome definition is applied.
The divergence in findings may also be explained by
racial differences. Recent publications suggest that an
Asian racial origin could be identified as a risk for dis-
ease progression in IgAN [18,19]. Despite the fact that
our study and the European study enrolled early IgAN
patients with similar baseline renal function and protein-
uria levels and used similar outcome definitions, renal
prognosis in our cohort was considerably different from
that observed in the European cohort. To clarify the
influence of ethnicity on these observations, a delicate
Table 5 Comparisons of definition and outcome of early IgAN with the previous studies
Hong Kong (‘00) Hong Kong (‘01) China (‘08) Europe (‘12) Korea (‘14)
N 45 (NA) 72 (10%) 177 (NA) 141 153 (8.8%)
Definition Cr < 1.3 mg/dL Cr < 120 μmol/L eGFR > 90 mL/min eGFR > 60 mL/min eGFR > 60 mL/min
Proteinuria < 0.4 g/day Proteinuria < 0.4 g/day Proteinuria < 0.4 g/day Proteinuria < 0.5 g/day Proteinuria < 0.5 g/day
HTN (−) HTN (−) HTN (−) HTN (−)
FU months 123 (60 –180) 84 (14–112) 111 (109–205) 108 (60– 180) 95 (38–207)
Age (years) 29 (15–57) 27 (15–50) 38 ± 16 23 (5–71) 26 (16–65)
Outcome
ESRD No 1 patient No No 6 patients
Cr ↑ 6 (13%) 5 (7%) 43 (24%) 5 (3.5%) 3 (2.1%)
Proteinuria ↑ 15 (34%) 24 (33%) 79 (46%) 21 (14.9%) 11 (18.3%)
HTN 11 (24%) 19 (26%) 68 (38%) 23 (16.3%) NA
Remission NA 10 (14%) 10 (6%) 53 (38%) 36 (25%)
NA, not applicable; Cr, creatinine; eGFR, estimated glomerular filtration rate; HTN, hypertension; ESRD, end stage renal disease.
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be performed.
Lead-time bias may also explain the different out-
comes in early IgAN. Because of variations in biopsy
practices, the disease is detected at different times in its
natural course. Even among early IgAN patients with
similar initial presentations, the duration of disease
could be different. Some patients visit the clinic im-
mediately after gross hematuria or incidentally detected
hematuria, while others visit several years after the initial
manifestation. However, clinicians can only conduct as-
sessments at the time of initial visit or biopsy. Therefore,
a comparison of these patients using only initial data
could be limited by lead-time bias.
Our data also showed that pathological changes in-
cluding IF can be important for renal risk prediction in
clinically early IgAN patients. More than 12% of patients
showed a more than moderate degree of tubulo-
interstitial changes. Furthermore, IF is an independent
predictor of ESRD progression in this study. Such results
are consistent with some previous studies [9,20,21] and
inconsistent with another study [6]. Although IgAN is
a glomerular disease, tubulo-interstitial injury via the
mesangio-podocytic-tubular crosstalk plays an important
role in mediating renal fibrosis and, ultimately resulting in,
renal failure [22]. In our study, mesangial hypercellularity
or interstitial inflammation was not associated with renal
progression. Those are considered relatively early renal in-
jury markers, whereas IF is regarded as relatively advanced
marker in IgAN patients with minor abnormalities. In-
deed, IF is one component of the Oxford classification, al-
though it is validated mostly in patients with proteinuria
of more than 1 g/day [23,24]. Our study results support
the applicability of the Oxford classification even in IgAN
patients with a minimal clinical presentation.We further demonstrated that hypoalbuminemia is a
significant predictor of renal outcome. These finding is
consistent with those in previous IgAN studies [4,25] as
well as those in other CKD studies [26,27]. Lower serum
albumin levels can be explained by the amount of pro-
teinuria, nutritional status or combined inflammation. In
our cohort, 7 patients showed reduced serum albumin
levels. Their proteinuria amount was ranged between
0.16 and 0.45 g/day. Three patients had combined in-
flammation, and one patient suffered from tuberculosis
and was subsequently malnourished. In other words, hy-
poalbuminemia may contribute to a poor renal outcome,
independently from proteinuria.
The particular strengths and insights gained from this
investigation include the long follow-up duration and
large sample size, which is specifically important in
IgAN research because of the insidious course of this
disease. We were able to assess hard outcomes such as
ESRD progression and mortality in this study. Moreover,
we were able to suggest racial differences in IgAN prog-
nosis by using baseline characteristics and outcome defi-
nitions similar to those used in the prior European
study. We were also able to alarm many nephrologists
and primary physicians who have managed clinically
early IgAN patients with ease, especially in Korea.
However, several shortcomings remain to be resolved.
First, the number of outcomes observed in our cohort
was too small despite the long follow-up duration. Lack
of events hampered our ability to perform robust multi-
variate predictive modeling. Second, this is a single-
center, retrospective study, and therefore, we could not
take into account diverse management strategies ac-
cording to individual clinicians. Although hard outcome
data were collected by both medical record review
and from a national registry or statistics, the last clinical
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not use the Oxford classification in this study. How-
ever, we were able to measure each component of
the Oxford classification semi-quantitatively, as shown in
Table 1. Lastly, we could not clarify the precise reason
for progression to ESRD among patients with initially
benign clinical presentations. We proposed different
outcome definitions, lead-time bias, and ethnicity as
potential explanations. However, we could not prove
these, and further sequential investigation is therefore
warranted.
Conclusions
In this study, we demonstrated that clinically early IgAN
does not always show a favorable outcome and may even
progress to ESRD. Patients with IF and hypoalbumin-
emia should be more aggressively monitored, especially
in Korea.
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